Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines.

作者: Thomas Schöndorf , Rainer Neumann , Carolin Benz , Martina Becker , Marion Riffelmann

DOI: 10.1007/978-3-642-19022-3_10

关键词: Cancer researchOvarian cancerCell cultureMultiple drug resistanceOncologyGlyceraldehyde 3-phosphate dehydrogenasePaclitaxelInternal medicineChemistryMessenger RNADoxorubicinCisplatin

摘要: The clinical observation of the multidrug resistance (MDR) phenotype is often associated with overexpression mdr1 gene, in particular respect to ovarian cancer. However, until now mdr1-inducing potential commonly used antineoplastics has been only incompletely explored. We performed short-term cultures six cancer cell lines (MZOV4, EFO27, SKOV3, OAW42, OTN14, MZOV20) exposed either blank medium or cisplatin, doxorubicin paclitaxel at concentrations related clinically achievable plasma peak concentration. A highly specific quantitative real-time RT-PCR was detect Mdr1 transcripts. mRNA contents were calibrated relation coamplified GAPDH mRNA. detectable each line. In 13 out 18 assays (72%) anticancer drug being tested induced transcription. No decrease concentration observed. Our data suggest that induction by one reasons for failure therapy but may vary individually.

参考文章(21)
Mark M. Baekelandt, Gunnar B. Kristensen, Ruth Holm, Jahn M. Nesland, Claes G. Tropé, P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Research. ,vol. 20, pp. 1061- 1067 ,(2000)
Xiaowei Yang, M. Page, P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncology Research. ,vol. 7, pp. 619- 624 ,(1995)
Friedlander Ml, Prognostic factors in ovarian cancer. Seminars in Oncology. ,vol. 25, pp. 305- 314 ,(1998)
Paula M. Fracasso, Mark F. Brady, David H. Moore, Joan L. Walker, Peter G. Rose, Laurie Letvak, Thomas M. Grogan, William P. McGuire, Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study Journal of Clinical Oncology. ,vol. 19, pp. 2975- 2982 ,(2001) , 10.1200/JCO.2001.19.12.2975
Mark Baekelandt, Gustav Lehne, Claes G. Tropé, István Szántó, Per Pfeiffer, Bengt Gustavssson, Gunnar B. Kristensen, Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer Journal of Clinical Oncology. ,vol. 19, pp. 2983- 2993 ,(2001) , 10.1200/JCO.2001.19.12.2983
Krishnansu Sujata Tewari, Ainura S. Kyshtoobayeva, Rita S. Mehta, Ing-Ru Yu, Robert A. Burger, Philip J. DiSaia, John P. Fruehauf, Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecologic Oncology. ,vol. 78, pp. 130- 136 ,(2000) , 10.1006/GYNO.2000.5837
J. Robert, Multidrug resistance in oncology: diagnostic and therapeutic approaches. European Journal of Clinical Investigation. ,vol. 29, pp. 536- 545 ,(1999) , 10.1046/J.1365-2362.1999.00495.X
A.M. Codegoni, M. Broggini, M.R. Pitelli, M. Pantarotto, V. Torri, C. Mangioni, M. D'Incalci, Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer Gynecologic Oncology. ,vol. 65, pp. 130- 137 ,(1997) , 10.1006/GYNO.1996.4609